{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:47:52Z","timestamp":1792226872446,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40272-020-00381-8","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T03:02:30Z","timestamp":1579662150000},"page":"113-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["New Developments in the Treatment of X-Linked Hypophosphataemia: Implications for Clinical Management"],"prefix":"10.1007","volume":"22","author":[{"given":"Vrinda","family":"Saraff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Nadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6304","authenticated-orcid":false,"given":"Wolfgang","family":"H\u00f6gler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"381_CR1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mam.2012.07.007","volume":"34","author":"IC Forster","year":"2013","unstructured":"Forster IC, Hernando N, Biber J, Murer H. Phosphate transporters of the SLC20 and SLC34 families. Mol Aspects Med. 2013;34:386\u201395.","journal-title":"Mol Aspects Med"},{"key":"381_CR2","doi-asserted-by":"crossref","first-page":"14564","DOI":"10.1073\/pnas.95.24.14564","volume":"95","author":"H Hilfiker","year":"1998","unstructured":"Hilfiker H, Hattenhauer O, Traebert M, Forster I, Murer H, Biber J. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci USA. 1998;95:14564\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"381_CR3","doi-asserted-by":"crossref","first-page":"C487","DOI":"10.1152\/ajpcell.00412.2001","volume":"282","author":"H Xu","year":"2002","unstructured":"Xu H, Bai L, Collins JF, Ghishan FK. Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)(2) vitamin D(3). Am J Physiol Cell Physiol. 2002;282:C487\u201393.","journal-title":"Am J Physiol Cell Physiol"},{"key":"381_CR4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.ki.5000148","volume":"69","author":"D Bacic","year":"2006","unstructured":"Bacic D, Lehir M, Biber J, Kaissling B, Murer H, Wagner CA. The renal Na+\/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone. Kidney Int. 2006;69:495\u2013503.","journal-title":"Kidney Int"},{"key":"381_CR5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3892\/ijmm.2015.2423","volume":"37","author":"S Liu","year":"2016","unstructured":"Liu S, Zhu W, Li S, Ma J, Zhang H, Li Z, et al. Bovine parathyroid hormone enhances osteoclast bone resorption by modulating V-ATPase through PTH1R. Int J Mol Med. 2016;37:284\u201392.","journal-title":"Int J Mol Med"},{"key":"381_CR6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/0026-0495(76)90124-4","volume":"25","author":"AM Parfitt","year":"1976","unstructured":"Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metabolism. 1976;25:909\u201355.","journal-title":"Metabolism"},{"key":"381_CR7","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.bone.2012.02.015","volume":"50","author":"Y Yu","year":"2012","unstructured":"Yu Y, Sanderson SR, Reyes M, Sharma A, Dunbar N, Srivastava T, et al. Novel NaPi-IIc mutations causing HHRH and idiopathic hypercalciuria in several unrelated families: long-term follow-up in one kindred. Bone. 2012;50:1100\u20136.","journal-title":"Bone"},{"key":"381_CR8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMe020098","volume":"347","author":"HM Kronenberg","year":"2002","unstructured":"Kronenberg HM. NPT2a\u2014the key to phosphate homeostasis. N Engl J Med. 2002;347:1022\u20134.","journal-title":"N Engl J Med"},{"key":"381_CR9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jbmr.1740","volume":"28","author":"J Bacchetta","year":"2013","unstructured":"Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res. 2013;28:46\u201355.","journal-title":"J Bone Miner Res"},{"key":"381_CR10","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/endo.143.8.8795","volume":"143","author":"T Shimada","year":"2002","unstructured":"Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002;143:3179\u201382.","journal-title":"Endocrinology"},{"key":"381_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3941","author":"W H\u00f6gler","year":"2019","unstructured":"H\u00f6gler W, Kapelari K. Oral iron for prevention and treatment of rickets and osteomalacia in autosomal dominant hypophosphatemia. J Bone Miner Res. 2019. https:\/\/doi.org\/10.1002\/jbmr.3941.","journal-title":"J Bone Miner Res"},{"key":"381_CR12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jbmr.544","volume":"27","author":"S Ichikawa","year":"2012","unstructured":"Ichikawa S, Austin AM, Gray AK, Econs MJ. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells. J Bone Miner Res. 2012;27:453\u201360.","journal-title":"J Bone Miner Res"},{"key":"381_CR13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bone.2008.10.040","volume":"44","author":"EG Farrow","year":"2009","unstructured":"Farrow EG, Davis SI, Ward LM, Summers LJ, Bubbear JS, Keen R, et al. Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets. Bone. 2009;44:287\u201394.","journal-title":"Bone"},{"key":"381_CR14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajhg.2010.01.006","volume":"86","author":"B Lorenz-Depiereux","year":"2010","unstructured":"Lorenz-Depiereux B, Schnabel D, Tiosano D, H\u00e4usler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet. 2010;86:267\u201372.","journal-title":"Am J Hum Genet"},{"key":"381_CR15","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/jbmr.1850","volume":"28","author":"SH Rafaelsen","year":"2013","unstructured":"Rafaelsen SH, Raeder H, Fagerheim AK, Knappskog P, Carpenter TO, Johansson S, et al. Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. J Bone Miner Res. 2013;28:1378\u201385.","journal-title":"J Bone Miner Res"},{"key":"381_CR16","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"381_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/8756-3282(91)90002-Z","volume":"12","author":"J Foldes","year":"1991","unstructured":"Foldes J, Balena R, Ho A, Parfitt AM, Kleerekoper M. Hypophosphatemic rickets with hypocalciuria following long-term treatment with aluminum-containing antacid. Bone. 1991;12:67\u201371.","journal-title":"Bone"},{"key":"381_CR18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bone.2017.02.003","volume":"97","author":"LF Gonzalez Ballesteros","year":"2017","unstructured":"Gonzalez Ballesteros LF, Ma NS, Gordon RJ, Ward L, Backeljauw P, Wasserman H, et al. Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. Bone. 2017;97:287\u201392.","journal-title":"Bone"},{"key":"381_CR19","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.clnu.2018.09.028","volume":"38","author":"S Uday","year":"2019","unstructured":"Uday S, Sakka S, Davies JH, Randell T, Arya V, Brain C, et al. Elemental formula associated hypophosphataemic rickets. Clin Nutr Edinb Scotl. 2019;38:2246\u201350.","journal-title":"Clin Nutr Edinb Scotl"},{"key":"381_CR20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/qjmed\/hct258","volume":"107","author":"AM Hall","year":"2014","unstructured":"Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM Mon J Assoc Physicians. 2014;107:261\u20139.","journal-title":"QJM Mon J Assoc Physicians"},{"key":"381_CR21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","volume":"26","author":"H Zoller","year":"2017","unstructured":"Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26:266\u201375.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"381_CR22","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","volume":"354","author":"E Berman","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006\u201313.","journal-title":"N Engl J Med"},{"key":"381_CR23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol. 2009;160:491\u20137.","journal-title":"Eur J Endocrinol"},{"key":"381_CR24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14:58.","journal-title":"Orphanet J Rare Dis"},{"key":"381_CR25","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1073\/pnas.73.12.4667","volume":"73","author":"EM Eicher","year":"1976","unstructured":"Eicher EM, Southard JL, Scriver CR, Glorieux FH. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci USA. 1976;73:4667\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"381_CR26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/geno.1997.4876","volume":"44","author":"M Grieff","year":"1997","unstructured":"Grieff M, Whyte MP, Thakker RV, Mazzarella R. Sequence analysis of 139 kb in Xp221 containing spermine synthase and the 5\u2032 region of PEX. Genomics. 1997;44:227\u201331.","journal-title":"Genomics"},{"key":"381_CR27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"ADHR Consortium","year":"2000","unstructured":"ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345\u20138.","journal-title":"Nat Genet"},{"key":"381_CR28","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Investig. 2014;124:1587\u201397.","journal-title":"J Clin Investig"},{"key":"381_CR29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15:435\u201355.","journal-title":"Nat Rev Nephrol"},{"key":"381_CR30","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26:1381\u20138.","journal-title":"J Bone Miner Res"},{"key":"381_CR31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/jc.2011-1319","volume":"97","author":"EA Imel","year":"2012","unstructured":"Imel EA, Econs MJ. Approach to the hypophosphatemic patient. J Clin Endocrinol Metab. 2012;97:696\u2013706.","journal-title":"J Clin Endocrinol Metab"},{"key":"381_CR32","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis. 2018;41:865\u201376.","journal-title":"J Inherit Metab Dis"},{"key":"381_CR33","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3:R13\u201330.","journal-title":"Endocr Connect"},{"key":"381_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.03.009","author":"A Rothenbuhler","year":"2019","unstructured":"Rothenbuhler A, Schnabel D, H\u00f6gler W, Linglart A. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism. 2019. https:\/\/doi.org\/10.1016\/j.metabol.2019.03.009.","journal-title":"Metabolism"},{"key":"381_CR35","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378:1987\u201398.","journal-title":"N Engl J Med"},{"key":"381_CR36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7:189\u201399.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"381_CR37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bone.2019.02.010","volume":"122","author":"TD Thacher","year":"2019","unstructured":"Thacher TD, Pettifor JM, Tebben PJ, Creo AL, Skrinar A, Mao M, et al. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic Rickets Severity Score. Bone. 2019;122:76\u201381.","journal-title":"Bone"},{"issue":"10189","key":"381_CR38","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet Lond Engl. 2019;393(10189):2416\u201327.","journal-title":"Lancet Lond Engl"},{"key":"381_CR39","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33:1383\u201393.","journal-title":"J Bone Miner Res"},{"key":"381_CR40","unstructured":"crysvita-epar-product-information_en.pdf [Internet]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf. Cited 4 July 2019."},{"key":"381_CR41","unstructured":"EuRRECa [Internet]. EuRRECa. https:\/\/eurreca.net\/. Cited 14 July 2019."},{"key":"381_CR42","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3:1321\u201334.","journal-title":"J Endocr Soc"},{"key":"381_CR43","doi-asserted-by":"crossref","first-page":"E2097","DOI":"10.1210\/jc.2011-0399","volume":"96","author":"M \u017divi\u010dnjak","year":"2011","unstructured":"\u017divi\u010dnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab. 2011;96:E2097\u2013105.","journal-title":"J Clin Endocrinol Metab"},{"key":"381_CR44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","volume":"33","author":"N Meyerhoff","year":"2018","unstructured":"Meyerhoff N, Haffner D, Staude H, W\u00fchl E, Marx M, Beetz R, et al. Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr Nephrol Berl Ger. 2018;33:447\u201356.","journal-title":"Pediatr Nephrol Berl Ger."},{"issue":"7","key":"381_CR45","first-page":"8349","volume":"33","author":"R Fuente","year":"2019","unstructured":"Fuente R, Gil-Pe\u00f1a H, Claramunt-Taberner D, Hern\u00e1ndez-Fr\u00edas O, Fern\u00e1ndez-Iglesias \u00c1, Alonso-Dur\u00e1n L, et al. MAPK inhibition and growth hormone: a promising therapy in XLH. FASEB J Off Publ Fed Am Soc Exp Biol. 2019;33(7):8349\u201362.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"issue":"3","key":"381_CR46","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2215\/CJN.04981107","volume":"3","author":"US Alon","year":"2008","unstructured":"Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol.\u00a02008;3(3):658\u201364.","journal-title":"Clin J Am Soc Nephrol"},{"key":"381_CR47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1172\/JCI112776","volume":"79","author":"T Nesbitt","year":"1987","unstructured":"Nesbitt T, Lobaugh B, Drezner MK. Calcitonin stimulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in hypophosphatemic mice. Evidence that the regulation of calcitriol production is not universally abnormal in X-linked hypophosphatemia. J Clin Investig. 1987;79:15\u20139.","journal-title":"J Clin Investig"},{"key":"381_CR48","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1056\/NEJMc1010928","volume":"364","author":"ES Liu","year":"2011","unstructured":"Liu ES, Carpenter TO, Gundberg CM, Simpson CA, Insogna KL. Calcitonin administration in X-linked hypophosphatemia. N Engl J Med. 2011;364:1678\u201380.","journal-title":"N Engl J Med"},{"key":"381_CR49","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00223-017-0382-0","volume":"102","author":"R Sullivan","year":"2018","unstructured":"Sullivan R, Abraham A, Simpson C, Olear E, Carpenter T, Deng Y, et al. Three-month randomized clinical trial of nasal calcitonin in adults with X-linked hypophosphatemia. Calcif Tissue Int. 2018;102:666\u201370.","journal-title":"Calcif Tissue Int"},{"key":"381_CR50","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2106\/00004623-198062070-00010","volume":"62","author":"GA Evans","year":"1980","unstructured":"Evans GA, Arulanantham K, Gage JR. Primary hypophosphatemic rickets. Effect of oral phosphate and vitamin D on growth and surgical treatment. J Bone Joint Surg Am. 1980;62:1130\u20138.","journal-title":"J Bone Joint Surg Am"},{"key":"381_CR51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.bpo.0000218531.66856.b7","volume":"26","author":"E Novais","year":"2006","unstructured":"Novais E, Stevens PM. Hypophosphatemic rickets: the role of hemiepiphysiodesis. J Pediatr Orthop. 2006;26:238\u201344.","journal-title":"J Pediatr Orthop"},{"key":"381_CR52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1302\/0301-620X.93B1.24788","volume":"93","author":"M Kocaoglu","year":"2011","unstructured":"Kocaoglu M, Bilen FE, Sen C, Eralp L, Balci HI. Combined technique for the correction of lower-limb deformities resulting from metabolic bone disease. J Bone Joint Surg Br. 2011;93:52\u20136.","journal-title":"J Bone Joint Surg Br"},{"key":"381_CR53","first-page":"626","volume":"22","author":"IH Choi","year":"2002","unstructured":"Choi IH, Kim JK, Chung CY, Cho T-J, Lee SH, Suh SW, et al. Deformity correction of knee and leg lengthening by Ilizarov method in hypophosphatemic rickets: outcomes and significance of serum phosphate level. J Pediatr Orthop. 2002;22:626\u201331.","journal-title":"J Pediatr Orthop"},{"key":"381_CR54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1067\/mpd.2003.119","volume":"142","author":"C Chaussain-Miller","year":"2003","unstructured":"Chaussain-Miller C, Sinding C, Wolikow M, Lasfargues J-J, Godeau G, Garab\u00e9dian M. Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. J Pediatr. 2003;142:324\u201331.","journal-title":"J Pediatr"},{"key":"381_CR55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2842.2011.02250.x","volume":"39","author":"MG Andersen","year":"2012","unstructured":"Andersen MG, Beck-Nielsen SS, Haubek D, Hintze H, Gj\u00f8rup H, Poulsen S. Periapical and endodontic status of permanent teeth in patients with hypophosphatemic rickets. J Oral Rehabil. 2012;39:144\u201350.","journal-title":"J Oral Rehabil"},{"key":"381_CR56","first-page":"69","volume":"72","author":"P Batra","year":"2006","unstructured":"Batra P, Tejani Z, Mars M. X-linked hypophosphatemia: dental and histologic findings. J Can Dent Assoc. 2006;72:69\u201372.","journal-title":"J Can Dent Assoc"},{"key":"381_CR57","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1601-0825.2006.01326.x","volume":"13","author":"C Chaussain-Miller","year":"2007","unstructured":"Chaussain-Miller C, Sinding C, Septier D, Wolikow M, Goldberg M, Garabedian M. Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral Dis. 2007;13:482\u20139.","journal-title":"Oral Dis"},{"key":"381_CR58","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00247-007-0503-4","volume":"37","author":"G Currarino","year":"2007","unstructured":"Currarino G. Sagittal synostosis in X-linked hypophosphatemic rickets and related diseases. Pediatr Radiol. 2007;37:805\u201312.","journal-title":"Pediatr Radiol"},{"key":"381_CR59","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3171\/2015.10.PEDS15273","volume":"17","author":"RA Vega","year":"2016","unstructured":"Vega RA, Opalak C, Harshbarger RJ, Fearon JA, Ritter AM, Collins JJ, et al. Hypophosphatemic rickets and craniosynostosis: a multicenter case series. J Neurosurg Pediatr. 2016;17:694\u2013700.","journal-title":"J Neurosurg Pediatr"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-020-00381-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:28:39Z","timestamp":1611188919000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-020-00381-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["381"],"URL":"https:\/\/doi.org\/10.1007\/s40272-020-00381-8","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"22 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"VS and WH were investigators for clinical studies sponsored by Ultragenyx and received honoraria and travel support from Kyowa Kirin for participation on advisory boards. WH received research grant support by Kyowa Kirin. RN has no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}